A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Purpose: In a preclinical drug screen, mithramycin was identified as a potent inhibitor of the Ewing sarcoma EWS-FLI1 transcription factor. We conducted a phase I/II trial to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of mithramycin in child...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancer Chemotherapy & Pharmacology Vol. 80; no. 3; pp. 645 - 653
Autores principales:	Grohar, Patrick, Glod, John, Peer, Cody, Sissung, Tristan, Arnaldez, Fernanda, Long, Lauren, Figg, William, Whitcomb, Patricia, Helman, Lee, Widemann, Brigitte, Grohar, Patrick J, Peer, Cody J, Sissung, Tristan M, Arnaldez, Fernanda I, Figg, William D, Helman, Lee J, Widemann, Brigitte C
Formato:	clinical trial research tables/charts Journal Article
Publicado:	Springer Nature Sep2017
Acceso en línea:	Ver este registro en EBSCOhost